Home » Business News » 2012 » November » November 5, 2012

MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 2012 American Society of Hematology Annual Meeting

November 5, 2012 - Munich, Germany

MorphoSys AG /MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208at2012 American Society of Hematology Annual Meeting. Processed andtransmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today thepublication of additional preclinical data on its two proprietary cancerprograms MOR208 and MOR202 in the online issue of the peer-reviewed medicaljournal BLOOD. The data sets further underline the potential of bothcompoundsto result in new treatment options for various forms of blood-borne cancer.Fulldata will be presented at the 2012 American Society of Hematology (ASH)annualmeeting on December 8-11, 2012 in Atlanta.

MOR208, an anti-CD19 antibody with a proprietary modification to the Fcportion,has successfully concluded a phase 1/2a clinical trial in chroniclymphocyticleukemia (CLL). The program is on track to enter clinical development innon-Hodgkin's lymphoma (NHL) and acute lymphoblastic leukemia (ALL). Thepreclinicalin vitro study to be presented at ASH examined MOR208's potential totriggerantibody-dependent cell-mediated cytotoxicity (ADCC) relative to a nativenon-engineered anti-CD19 antibody. In the study, MOR208 showedsignificantlyenhanced cytotoxicity triggering killing of cancer cells derived from bothpediatric and adult patients with ALL. MOR208 was twice as effective as thenon-engineered antibody and required lower antibody levels and lowerpresence ofeffector cells.

MOR202, an anti-CD38 HuCAL antibody, is currently being tested in a phase1/2astudy in patients with relapsed or refractory multiple myeloma (MM). Havingpreviously identified ADCC as an effector mechanism of MOR202, thepreclinicaldata to be presented at ASH demonstrate the antibody's capability to inducekilling of MM patient cells via antibody dependent cellular phagocytosis(ADCP)as an additional potent mechanism.

"These findings for our proprietary cancer programs MOR202 and MOR208 areveryencouraging and highlight the significant potential of both candidates.MOR208may represent a promising approach for treatment of pediatric and adultALL,"commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG."ForMOR202, the additional effector mechanism bodes well for future clinicaldevelopment in multiple myeloma."

In total, MorphoSys currently has four proprietary clinical programsongoing,namely MOR208 and MOR202, as well as MOR103, a fully human HuCAL antibodydirected against GM-CSF (granulocyte macrophage-colony stimulating factor),thatis being developed in rheumatoid arthritis and multiple sclerosis.

The full abstracts are available on

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.TheCompany's AbD Serotec unit uses HuCAL and other antibody technologies togenerate superior monoclonal antibodies for research and diagnosticapplications.

Together with its pharmaceutical partners, MorphoSys has built atherapeuticpipeline of more than 70 human antibody drug candidates for the treatmentofcancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.Withits ongoing commitment to new antibody technology and drug development,MorphoSys is focused on making the healthcare products of tomorrow.MorphoSys islisted on the Frankfurt Stock Exchange under the symbol MOR. For regularupdatesabout MorphoSys, visit

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®,RapMAT®, arYla®, Ylanthia®and 100 billion high potentials® are registered trademarks ofMorphoSys AGSlonomics® is a registered trademark of Sloning BioTechnology GmbH, asubsidiaryof MorphoSys AG.

This communication contains certain forward-looking statements concerningtheMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from the Company'sassumptions, actual results and actions may differ from those anticipated.MorphoSys does not intend to update any of these forward-looking statementsasfar as the wording of the relevant press release is concerned.

Media Release:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Email Contact


Comment on this story